Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - topotekanas - ovarian neoplasms; uterine cervical neoplasms; small cell lung carcinoma - antinavikiniai vaistai - hycamtin kapsulės yra skirtas monoterapijai gydyti suaugusiems pacientams, sergantiems recidyvuojančia nesmulkialąsteliniu plaučių vėžiu (spv), kuriems gydymą pirmos eilutės režimas laikomas tinkama. topotecan skiriamas pacientams, sergantiems metastazavusios kiaušidžių po nesėkmės pirmos eilės ar vėlesnis gydymas. hycamtin kapsulės yra skirtas monoterapijai gydyti suaugusiems pacientams, sergantiems recidyvuojančia nesmulkialąsteliniu plaučių vėžiu (spv), kuriems gydymą pirmos eilutės režimas laikomas tinkama.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

actavis group ptc ehf. - flukonazolas - kietoji kapsulė - 150 mg - fluconazole

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

nenurodyta - vinkristinas - injekcinis tirpalas - 1 mg/ml - vincristine

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakonazolas - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics sisteminiam vartojimui - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 ir 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 ir 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 ir 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invazinių aspergillosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b arba itraconazole, arba pacientams, kurie netoleruoja tokių vaistų;- fusariosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b, arba pacientams, kurie netoleruoja amphotericin b;- chromoblastomycosis ir mycetoma pacientams, sergantiems liga, kuri yra ugniai atsparios į itraconazole, arba pacientams, kurie netoleruoja itraconazole;- coccidioidomycosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b, itraconazole ar fluconazole, arba pacientams, kurie netoleruoja tokių vaistų;- burnos ir ryklės kandidozė: kaip pirmos eilės gydymas pacientams, kurie serga sunkia liga ar yra imuninės sistemos sutrikimų, į kuriuos atsako į aktualius terapija, tikimasi, bus prastas. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

roche registration gmbh - obinutuzumab - leukemija, limfocitinė, lėtinė, b-ląstelė - antinavikiniai vaistai - lėtine limfocitine leukemija (lll)gazyvaro kartu su chlorambucil fluorouracilu ir folino suaugusių pacientų, kurių anksčiau negydytų lėtine limfocitine leukemija (lll) ir su comorbidities, todėl jiems netinka visą dozę fludarabine pagrįstas terapija (žr. skyrių 5. follicular limfoma (fl)gazyvaro kartu su chemoterapija, po gazyvaro priežiūros terapija pacientams, siekiant atsakymo, yra nurodyta gydomi pacientai, sergantys anksčiau negydytų advanced follicular limfoma. gazyvaro kartu su bendamustine po gazyvaro priežiūrai skiriamas pacientams, sergantiems follicular limfoma (fl), kurie neatsakė, ar kuris progresavo metu ar iki 6 mėnesių po gydymo rituximab arba rituximab-kurių sudėtyje režimas.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

actavis group ptc ehf - topotekanas - uterine cervical neoplasms; small cell lung carcinoma - antinavikiniai vaistai - topotekano monoterapija skiriama pacientams, turintiems recidyvuojantį smulkialąstelinį plaučių vėžį (sclc), gydyti, kuriems pakartotinis gydymas pirmosios eilės tvarka nėra tinkamas. topotecan kartu su cisplatina skiriamas pacientams su karcinomos, gimdos kaklelio periodinis po radioterapijos ir pacientams, sergantiems etape ivb ligos. pacientams, sergantiems prieš sąlyčio su cisplatina būtinas nuolatinis gydymas nemokamai intervalas pagrįsti gydymo derinys.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

eagle laboratories ltd.    - topotecan (as hydrochloride) - carcinoma; small cell lung carcinoma - antinavikiniai ir imunomoduliatoriai - topotekano monoterapija skiriama pacientams, turintiems recidyvuojantį smulkialąstelinį plaučių vėžį (sclc), kuriems pakartotinis gydymas pirmojo gydymo režimu laikomas netinkamu. topotecan kartu su cisplatina skiriamas pacientams su karcinomos, gimdos kaklelio periodinis po radioterapijos ir pacientams, sergantiems etape ivb ligos. pacientams, sergantiems prieš sąlyčio su cisplatina būtinas nuolatinis gydymas nemokamai intervalas pagrįsti gydymo derinys.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

viiv healthcare bv - lamivudine zidovudinas - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - combivir is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pierre fabre medicament - vinfluninas - carcinoma, transitional cell; urologic neoplasms - antinavikiniai vaistai - javlor skiriamas skirtas gydyti suaugusiems pacientams su išplitusiu ar metastazavusiu pereinamojo laikotarpio ląstelių karcinoma urothelial takų po nesėkmingo ankstesnio platinos preparatų režimas. saugumą ir veiksmingumą vinflunine nebuvo tirtas pacientams, kurių veiklos statusą ≥ 2.